B. Metzler seel. Sohn & Co. AG Sells 195 Shares of ResMed Inc. (NYSE:RMD)

B. Metzler seel. Sohn & Co. AG lowered its position in ResMed Inc. (NYSE:RMD) by 2.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 6,830 shares of the medical equipment provider’s stock after selling 195 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in ResMed were worth $1,562,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in shares of ResMed in the fourth quarter worth about $39,000. BankPlus Trust Department purchased a new position in ResMed in the 4th quarter valued at approximately $44,000. Rosenberg Matthew Hamilton bought a new stake in ResMed during the 4th quarter valued at $54,000. SBI Securities Co. Ltd. purchased a new stake in shares of ResMed during the fourth quarter worth $67,000. Finally, Kentucky Trust Co bought a new position in shares of ResMed in the fourth quarter worth $82,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. KeyCorp increased their price objective on ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. StockNews.com cut shares of ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Friday, January 31st. JPMorgan Chase & Co. boosted their price target on shares of ResMed from $270.00 to $286.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Finally, Piper Sandler upped their price target on shares of ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and a consensus price target of $249.73.

ResMed Trading Up 0.2 %

NYSE RMD opened at $222.78 on Thursday. The stock’s 50-day simple moving average is $232.37 and its two-hundred day simple moving average is $237.54. ResMed Inc. has a twelve month low of $172.19 and a twelve month high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $32.72 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Research analysts forecast that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.95%. The ex-dividend date was Thursday, February 13th. ResMed’s dividend payout ratio is presently 25.03%.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the sale, the chief executive officer now owns 455,472 shares in the company, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares in the company, valued at $18,695,249.98. This represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,940 shares of company stock worth $9,164,385 over the last three months. Company insiders own 0.71% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.